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Abstract.  A panel of 21  c~-subunit (CDlla) and 10 
/3-subunit  (CD18)  anti-LFA-1  mAbs was screened for 
ability to activate LFA-1. A  single anti-CDlla mAb, 
MEM-83,  was identified which was able to directly in- 
duce the binding of T  cells to purified ICAM-1  im- 
mobilized on plastic. This ICAM-1  binding could be 
achieved by monovalent Fab fragments of rnAb MEM- 
83 at concentrations equivalent to whole antibody, was 
associated with appearance of the "activation reporter" 
epitope detected by mAb 24,  and was completely in- 
hibited by anti-ICAM-1 and LFA-1 blocking mAbs. 
The epitope recognized by mAb MEM-83 was distinct 
from that recognized by mAb NKI-L16,  an anti-CDlla 
mAb previously reported to induce LFA-1 activation, 
in that it was constitutively present on freshly isolated 
peripheral blood mononuclear cells and was not diva- 
lent cation dependent for expression. The ICAM-1 
binding activity induced by mAb MEM-83 was, how- 
ever, dependent on the presence of Mg  2+ divalent cat- 
ions.  Using an in vitro-translated CDlla cDNA dele- 
tion series, we have mapped the MEM-83 activation 
epitope to the "I" domain of the LFA-1 ot subunit. 
These studies have therefore identified a novel LFA-1 
activation epitope mapping to the I domain of LFA-1, 
thereby implicating this domain in the regulation of 
LFA-1 binding to ICAM-1. 
YMPHOCYTE function-associated antigen-1 (LFA-W is 
an tx/fl heterodimeric  molecule (CD1  la/CD18) which 
belongs to the if2 leukocyte integrin family of adhe- 
sion receptors (for review see Springer,  1990; Pardi et al., 
1992),  LFA-1 is expressed  on all leukocytes and mediates 
both heterotypic and homotypic cellular adhesion events be- 
tween leukocytes and a broad range of other cell types that 
express at least one of  the three counter-structures for LFA-I 
thus far identified, namely, intercellular  adhesion molecule-1 
(ICAM-1) (Rothlein and Springer, 1986), ICAM-2 (Staunton 
et al.,  1989), and ICAM-3  (de Fougerolles  and Springer, 
1992).  The integfins  are not constitutively  avid  for their 
ligands but exhibit a rapid and inducible change in avidity 
upon activation of  the cells on which they are expressed. For 
example, in the case of LFA-1 expressed on T cells, stimula- 
tion via the T cell receptor/CD3 complex results in a tran- 
sient increase in avidity of LFA-1 for ICAM-1, peaking at 
10-30 min,  followed by a return to low avidity by  1-2 h 
(Dustin and Springer,  1989; van Kooyk et al.,  1989). 
The mechanism by which remote triggering can generate 
such an "inside-out" signal and transduce a change in ligand- 
binding  ability  to  the extracellular domains of LFA-1  is 
poorly understood. However, the cytoplasmic tails of the t~ 
and/3 chains of LFA-1 and other integrins have been shown 
to be involved in transmitting  the ~inside-out" signal to the 
extracellular domains (Hibbs  et al.,  1991; O'roole et al., 
1991). The ligand binding pocket of the integrins is thought 
1. Abbreviations used in this paper: ICAM-1, intercellular adhesion mole- 
cule-I; LFA-I, lymphocyte function-associated antigen-l; PdBu,  phorbol 
dibutyrate. 
to be formed  by both the c~ and ~ subunits, since specific se- 
quences contained in each subunit are necessary for binding 
of fibrinogen to the integrin GPIlb-HIa, the most extensively 
studied integrin receptor/ligand pair (D'Souza et ai.,  1988, 
1991; Charo et al., 1991). Ligand binding is regulated by the 
presence of divalent  cations  (Gailit  and Ruoslahti,  1988; 
Dransfield et al.,  1992b), which bind to the metal binding 
domains common to all integrins (Smith and Cheresh, 1991; 
Gulino et al., 1992). In contrast, no information is available 
on the functional role of the inserted (or "I") domain, which 
is present only in the o~ chains of the three leukocyte inte- 
grins, LFA-1, CR3/Mac-1, and p150/95 (Larson et al., 1989) 
and two members of the ~  family of integrins,  VLA-1 and 
VLA-2 (Ignatius et al.,  1990; Takada and Hemler, 1989). 
The integrin ~F' domains belong to the superfamily of  type 
A domain proteins (Colombatti  and Bonaldo,  1991). They 
share homology with the prototype molecule of this super- 
family, the A domain of yon W'dlebrand factor, and several 
globular domains found in complement factors B and C2, as 
well as the extracellular  matrix proteins collagen type VI and 
cartilage matrix protein.  In yon Willebrand factor multiple 
ligand  binding  sites  have been mapped to the A  domain 
repeats, including sites for platelet glycoprotein Ib, heparin, 
and collagen types I and HI (Sadler, 1991). Although the/31 
integfins VLA-1 and VLA-2 act as collagen-binding recep- 
tors on various cell types, including melanocytes, fibroblasts, 
and platelets (for review see Hemier, 1990), the I domain ap- 
pears not to confer similar collagen binding ability to the/32 
integrins  on leukocytes.  Collagen  binding  by T  cells  and 
monocytes was found to be associated exclusively  with VLA-2, 
despite the fact that T cells expressed the I domain contain- 
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pressed all five I domain containing  integrins  (Goldman et 
al.,  1992). To date, no functional role has been recognized 
for the I domain in/32 integrins. 
mAbs have been useful for demonstrating the existence of 
distinct conformational states in integrins during their con- 
version to the ligand-binding  conformation.  For example, 
mAbs 24 and 7E3 are antibodies that detect neo-epitopes ex- 
pressed only by the high avidity conformers of the ~2 inte- 
grins and CR3/Mac-1,  respectively, thereby acting as inte- 
grin  "activation  reporters"  (Dransfield  and  Hogg,  1989; 
Dransfield et al.,  1992b; Altieri and Edgington,  1988).  A 
second group of mAbs, represented by NKI-L16, specific for 
the  LFA-1 ot subunit  (Keizer et al.,  1988),  and KIM-127, 
specific for the common/32 subunit (Robinson et al.,  1992), 
are capable of directly inducing the ligand-binding  confor- 
mation of LFA-1, in the putative absence of remote triggering 
and "inside-out" signals. 
In this report, we screened a panel of 31 anti-LFA-1 mAbs 
and identified an ot-subunit mAb, MEM-83, that was capable 
of directly inducing the ICAM-1 ligand-binding  conforma- 
tion  of LFA-1. The  epitope  recognized  by  MEM-83  was 
mapped to the I domain, thereby implicating this domain in 
the regulation of LFA-1 ligand-binding  affinity. 
Material and Methods 
Monoclonal Antibodies 
mAb MEM-83 was generously provided by Dr. V. Horejsi and has been pre- 
viously shown to recognize the c~ subunit of LFA-1 (Bazil et al.,  1990; 
Schmidt, 1989; data not shown). Anti-CDlla mAbs MEM-83, 38, and 24, 
anti-CD8 mAb 14, anti-ICAM-1 mAb 15.2 (Dransfield et al., 1992a), and 
nonreactive control mAb 52U were purified by protein A chromatography 
as previously described (Dransfield and Hogg, 1989) and were used at 5-10 
#g/mi.  The remaining mAbs were obtained from Dr.  Reinhold Schmidt 
from the Leukocyte Typing Workshop IV (Schmidt, 1989) and were used 
as ascitic fluids, diluted between 1:100 and 1:1,000. These antibodies in- 
cluded the anti-CDlla mAbs MHM24,  122.2A5,  BU-49, GRT22,  MEM- 
30, 2F12, Fl10.22, GRS3, HIll1, MI0, 0501, MEM-95, 25.3.1, 459, BU-17, 
YTH 81.5,  1524,  TMD3-1, and CC5 ID7; and the anti-CD18 mAbs H-52, 
MHM23, TS1/18, M232, ICll, CLB-54, YFC 51.1, YFC 118.3, GRF1, and 
IB-4. Direct FITC conjugates of mAb 24 were prepared as previously de- 
scribed (Harlow and Lane, 1988) and were used at 5 #g/ml. Fab fragments 
were prepared by papain digestion (1% wt/wt) of intact MEM-83 (IgG1) or 
38 (IgG2a), in 0.1 M sodium acetate, pH 5.5,  1 mM EDTA, 20 mM L-CYS- 
teine for 4  h  at 37~  followed by blocking with 75  mM iodoacetamide 
(Harlow and lane, 1988). Any intact antibody and Fc fragments were sepa- 
rated from Fab fragments by extensive adsorption with protein A-coupled 
Sepharose (Pharrnacia LKB Biotechnology, Uppsala, Sweden) followed by 
size  exclusion chromatography  over a  100  x  1.9-cm  Sephacryl  $200 
column (Pharmacia LKB Biotechnology).  Purity of Fab fragments was 
confirmed by silver staining of SDS-PAGE gels (Silver Stain Plus, Bio Rad 
Labs., Hercules, CA). 
Cells and Cell Lines 
Activated  T  cells  were  expanded  from  unstimulated  peripheral  blood 
mononuclear cells by treatment with 1 #g/ml phytohaemagglutinin for 4 d, 
followed by culture in RPMI 1640 supplemented with 10%  FCS and 20 
ng/ml rIL-2, as previously described (Dransfield et al., 1992b). T cells were 
used after 1-2 wk of culture, after the removal of IL-2 from the culture 
medium for 2-3 d  in order to induce quiescence. Such cells served as a 
model for the analysis ofT cell activation (Cantrell and Smith, 1984).  The 
human lymphoblastoid JY B cell and Jurkat T cell lines were maintained 
in RPMI 1640 supplemented with 10%  FCS. 
ICAM-1 Binding Assay 
An ICAM-1  fusion protein consisting of the first three domains of ICAM-1 
fused to a human IgGl Fc fragment (ICAM-1Fc)  was obtained from Drs. 
A. Berendt and A. Craig (Berendt et al.,  1992) and purified by protein A 
chromatography. 40 #1 of ICAM-1Fc (20 #g/ml) was added to each well of 
a flat-bottomed 96-well plate (Immulon 1, Dynatech Labs. Inc., Chantilly, 
VA) and centrifuged at 75 g for 1 min before overnight incubation at 4~ 
Before the binding assay, nonspecific sites were blocked with 2.5% BSA in 
PBS without divalent cations (PBS-A) for 2  h  at room temperature and 
washed four times with PBS-A and once in Hepes buffer (20 mM Hepes, 
140 mM NaCI, 2 mg/ml D-glucose, pH 7.4). Quantitation of T cell binding 
to ICAM-1Fc plates was performed as previously described (Dransfield et 
al.,  1992a).  Briefly,  5  ￿  107 cultured T cells were labeled with 200 #Ci 
51CrO42- (Amersham Life Sciences, Amersham, U.K.) and washed three 
times in the appropriate assay medium supplemented with 0.2 % BSA (frac- 
tion V, Sigma Chemical Company Ltd., Dorset, U.K.). The medium used 
in the binding assay was either RPMI  1640  or a defined divalent cation- 
containing medium consisting of Hepes buffer supplemented with various 
combinations of 1 mM each of CaCI2,  1 mM MgCI2,  1 mM EDTA, or 1 
mM EGTA. 51Cr-labeled  T cells (2.5  x  10  s in a 50-#1 vol) were added to 
each well of an ICAM-IFc-coated 96-well plate, in the presence or absence 
of 50 #1 of mAbs MEM-83, 38, 15.2, or control mAb, incubated on ice for 
15 min, centrifuged at 300 g for 1 min and incubated an additional 30 min 
at 37~  T cells that remained bound to ICAM-IFc plates after five washes 
with prewarmed RPMI were lysed in 1% Triton X-100 and the incorporated 
radioactivity was measured using a  Betaplate counter (LKB Instruments 
Inc., Bromma, Sweden). 
Homotypic Aggregation 
2.5  ￿  105 cultured T cells were added in a 100-#1 vol to each well of a 96- 
well plate and homotypic aggregation was semiquantitatively determined 
after 2 h at 37~  as previously described by the scoring method of Kansas 
and Tedder (1991). Aggregation of cells was read as follows: 0  =  no cluster 
formation (<10% of cells aggregated); 1 =  occasional clusters containing 
10-20 cells (<20% of cells aggregated); 2 =  50% of cells in medium-sized 
aggregates with the remainder as single cells; 3  =  majority of cells in 
medium-to-large-sized  aggregates (>80% of cells aggregated); 4  =  >90% 
of cells in large aggregates. 
Immunofluorescence 
Flow cytometry was performed as previously described (Dransfield et al., 
1992b).  Briefly,  los cultured T  cells or human cell lines, JY and Jurkat, 
were incubated for 20 min on ice with purified mAbs MEM-83, 38, or non- 
reactive control 52U (5 #g/ml), followed by a second incubation with FITC- 
conjugated goat anti-mouse immunoglobulin secondary antibody (50 #1 of 
1:100  dilution;  Nordic  Immunology,  Netherlands).  After  appropriate 
washes, cells were then fixed in 0.2 ml 5.5 % formaldehyde in PBS-A. mAb 
24 was used as a 1:50 dilution of FITC-conjugated mAb (5 #g/ml) with incu- 
bation performed for 30 rain at 37~  Flow cytometric analysis of antibody- 
labeled cells was performed by determining mean fluorescence intensity 
using a  FACScan (Becton Dickinson Immunocytometry Sys.,  Mountain 
View, CA) fitted with a logarithmic amplifier. 
PCR AmpUcation of  Fragments  from Cloned cDNA 
and from cDNA Libraries 
To construct the CDlla deletion series, fragments of LFA-1 eDNA were 
PCR amplified from a eDNA clone, 3R1, provided by Dr. T. Springer (Lar- 
son et al.,  1989) and from an HBP-ALL library made in CDM8 provided 
by Dr. D. Simmons, Oxford. The 5' PCR primers were designed to contain 
a  BamHI  restriction site,  a  Kozak  sequence to  maximize translational 
efficiency, an in-frame methionina, and a 24-bp hybridizing sequence corre- 
sponding to the 5' end of the desired fragment (Stanley,  P., J. E. Harvey, 
P. A. Bates, R. I. Bennet, and N. Hogg, manuscript in preparation). The 
3' primer consisted of the hybridizing sequence plus a HindIH restriction 
site. In this manner, a "nested" series of constructs with successive domain 
deletions starting  from the NH2  terminus of the  LFA-1 ct  subunit  was 
generated with each fragment terminating within domain VII (see Fig. 8 A). 
PCR  amplifications  were  carried  out  using  a  GeneAmp  TM  DNA  am- 
plification kit with Taq DNA polymerase (Perkin-Elmer Corp., Norwalk, 
CT) according to the manufacturer's instructions. Thirty amplification cy- 
cles consisting of 2 rain at 94~  2 min at 59~  and 9.9 min at 70~  were 
used, followed by a 9.9-rain extension at 70~ 
In vitro Transcription-Translation 
Transcription and translation of the nested CD1 la cDNA deletion series were 
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tem (Promega Corp., Madison, WI) according to manufacturer's instruc- 
tions.  1 #g of cloned DNA in Bluescript  TM KS  + phagemid served as the 
template for the reaction, which was carded out for 2 h at 30~  in a 50-#1 
vol and in the presence of [35Slmethionine  (Amersham Corp.) and 50% by 
volume rabbit reticulocyte lysate. 
Immunoprecipitation of I~anslation  Products 
After translation, 25 #1 of2x EIA buffer (500 mM NaCI, 100 mM Hepes, 
pH 7.0, 0.2 % NP-40) was added to an equal volume of translation product 
and the total volume of the precipitation made up to 200 #1 with lx  EIA 
buffer.  The primary incubation was carded out in the presence of 3 #g of 
purified mAbs MEM-83 or 14 at 4~  for 3-5 h, before the addition of 20 
#1 (packed volume) of Sepharose-protein A beads. The immunoprecipita- 
tions  were incubated an  additional  3-5  h  at 4~  before harvesting the 
Sepharose beads by a brief 30-s microcentrifugation. 10 #1 of the supernate 
was removed for monitoring of the translation efficiency of each fragment 
by SDS-PAGE. The remaining lysate was discarded and the beads washed 
three times with 1￿  EIA buffer plus 0.1% NP-40, and twice with lx  EIA 
buffer alone. Approximately 25 #1 of electrophoresis reducing buffer was 
added to the beads before SDS-PAGE analysis on a 9 % acrylamide separat- 
ing gel.  Gels were treated with EN3HANCE  TM  (New England Nuclear, 
Boston, MA) before autoradiography. 
Results 
The Anti-CD11a mAb MEM-83 Directly Induces T Cell 
Binding to ICAM-1 
Homotypic aggregation induced by mAbs and by phorbol es- 
ters has been previously used as a model of LFA-1/ICAM- 
1-dependent cell adhesion (Patarroyo et al.,  1985; Rothlein 
and Springer, 1986; Keizer et al., 1988; Kansas and Tedder, 
1991;  Koopman et al.,  1990).  In this  study, a panel of 21 
c~-subunit  (CDlla)  and  10  fl-(CD18)  subunit  anti-LFA-1 
mAbs were screened for their ability to induce homotypic 
aggregation and binding of T cells to ICAM-1  immobilized 
on plastic. None of the/3-subunit mAbs in the panel induced 
either aggregation or ICAM-1  binding (Fig. 1). Although 12 
of the 21 ~-subunit mAbs were capable of inducing homo- 
typic aggregation, only one of  these, mAb MEM-83, induced 
ICAM-1 binding. Therefore, homotypic aggregation induced 
by anti-CD1 la mAbs was not predictive of ICAM-1 binding. 
ICAM-1 Binding Induced by mAb MEM-83 Is Specific 
To further investigate the means by which bivalent antibodies 
caused homotypic aggregation and ICAM-1  binding, mono- 
valent Fab fragments were made from mAbs MEM-83 and 
38. mAb 38 was chosen as a representative anti-CDlla mAb 
that could induce homotypic aggregation of T cells but not 
binding to ICAM-1. Other aggregating mAbs were not avail- 
able in sufficient quantities to carry out similar analysis. In 
light of the recent findings by Cyster and Williams (1992) 
that Fab fragments of anti-CD43 mAbs could spontaneously 
aggregate in solution and mediate a multivalent homotypic 
aggregation event in lymphocytes, we took great care to use 
Fab fragments immediately after chromatographic purifica- 
tion on a Sephacryl $200 size exclusion column. Fab frag- 
ments eluted from the column at a molecular mass of 50 kD 
and  were  free  of any  intact  antibody  or  multivalent  ag- 
gregates by silver staining of SDS-PAGE gels under non- 
reducing conditions (Fig. 2). Fab fragments of mAb MEM- 
83 were capable of inducing both homotypic aggregation and 
ICAM-1  binding, both effects being completely inhibited by 
anti-ICAM-1  mAb  15.2  (Fig.  3).  Binding  of T  cells  to 
ICAM-1  was  also blocked with selected anti-LFA-1 mAbs 
(data not shown).  Titration curves demonstrated that Fab 
fragments of mAb MEM-83 were equivalent to whole anti- 
body in their ability to bind T cells by FACS  |  analysis (data 
not shown) or to promote T cell binding to ICAM-1 on plas- 
tic, at concentrations as low as 50 ng/ml (Fig. 4).  The ki- 
netics  of the  ICAM-1  binding  response induced by mAb 
MEM-83 were similar to those observed for phorbol esters, 
consisting of maximal binding by  10--30 min of treatment 
followed by a  plateau (data not shown).  In contrast to the 
results obtained with mAb MEM-83, Fab fragments of mAb 
Figure 1. Screen of CD1 la and 
CD18  panel  of  mAbs for 
homotypic  aggregation and 
ICAM-1 binding by T  cells. 
Human T  cells  were treated 
with  saturating doses  of the 
indicated mAbs and evaluated 
after 2 h of incubation at 37~ 
for  homotypic  aggregation 
(scale  of  semi-quantitative 
scoring  =  0--4, as described 
in  Materials  and  Methods) 
and after 30 min for binding of 
51Cr-labeled cells  to  ICAM- 
1Fc-coated  96-well  plates 
(quantitated  as  cpm  of  the 
bound T cell fraction). Repre- 
sentative results from a single 
experiment are shown (mini- 
mum n = 2 for any mAb) with 
each bar representing the av- 
erage  of  incubations per- 
formed in triplicate. 
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size exclusion chromatography. Fab frag- 
ments  of  MEM-83 were  generated  by 
papaln digestion of intact antibody, removal 
of Fc fragments and undigested antibody by 
protein  A-Sepharose  beads,  followed by 
size  exclusion  chromatography  over  a 
Sephacryl $200 column as shown. The mo- 
lecular size markers used during chroma- 
tography were alcohol dehydrogenase (150 
kD), BSA (66 kD), and carbonic anhydrase 
(29 kD). The inset depicts 2/~g mAb MEM- 
83, as intact antibody (Ig) or as eluted Fab 
fragments (Fab), analyzed on a 7.5 % SDS- 
PAGE gel  run under  nonreducing condi- 
tions and silver stained. The molecular size 
markers are indicated in the first lane. 
38 were unable to induce homotypic aggregation and ag- 
gregates formed using whole antibody were not inhibited by 
anti-ICAM-1 antibody (Fig. 3). These results suggested that 
mAb MEM-83 was capable of  directly inducing a conforma- 
tion of LFA-1 that exhibited an increased avidity for ligand 
ICAM-1,  an effect that  was  independent of any antibody- 
mediated  cross-linking properties,  mAb  38,  on the other 
hand, required bivalent antibody to cause formation of  homo- 
typic aggregates and demonstrated no ability to directly in- 
duce binding to ICAM-1. 
mAb MEM-83 Induces Expression of the "Activation 
Reporter" 24 Epitope on LFA-1 
To further confirm that mAb MEM-83, but not 38, was capa- 
ble of directly inducing the ligand-binding conformation of 
LFA-1, we examined expression of the "activation reporter" 
24 epitope on LFA-1 (Dransfield et al., 1992b). This experi- 
ment demonstrated clearly that preincubation of T cells with 
MEM-83,  but not 38,  resulted in exposure of the 24 neo- 
epitope on LFA-1 (Fig. 5). Nonreactive mAb 52U and phor- 
bol dibutyrate (PdBu) treatment were included as negative 
and  positive  controls  of  24  epitope  expression.  Cross- 
blocking of the 24 epitope by MEM-83 or 38 was ruled out 
in experiments that examined the effects of  either mAb on the 
binding of mAb 24 in the presence of 100/~M Mn  2+ (data 
not shown), which causes constitutive 24 epitope expression 
(Dransfield et al.,  1992b). 
Expression of the MEM-83 Epitopes on Lymphoid 
Cells Is Not Cation Dependent 
The anti-CDlla mAb NKI-L16, which has previously been 
reported to possess LFA-1 activating properties, recognizes 
an epitope that is Ca  ~+ dependent and is weakly expressed 
on fresh peripheral blood T cells, though well expressed on 
all cultured lymphoid cells (van Kooyk et al., 1991). In con- 
trast to NKI-L16, the MEM-83 epitope was found to be con- 
Figure  3. Effect of  monovalent  Fab fragments ofmAbs 
MEM-83 and 38 on  homotypic  aggregation  and ICAM-1 
binding.  The homotypic  aggregation and  ICAM-1 
binding assays were carried out as described in Fig. 1, 
in the presence and absence of anti-ICAM-1 mAb 
15.2 (5 ~g/ml). Results from a single experiment are 
shown; each bar represents the average of incubations 
performed in triplicate. Purified intact mAb and Fab 
fragments were used at saturating doses of 2 ~g/ml. 
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Figure 4. Titration  of the ICAM-1 binding-effect induced by intact 
antibody and Fab fragments of mAb MEM-83.  Monovalent  Fab 
fragments of mAb MEM-83 were prepared as described in the leg- 
end to Fig. 2. Flow cytometric analysis shows that Fab fragments 
of  MEM-83 recognize LFA-1 on T cells at titers equivalent to whole 
antibody (data not shown).  Results  from a single  experiment are 
shown, representative  of three similar experiments. 
C 2+ 
stitutively  expressed  on  freshly  isolated  lymphocytes and 
monocytes and all human leukocytic cell lines studied,  in- 
cluding the JY B cell and Jurkat T cell lines (data not shown). 
The binding ofmAb MEM-83 to cultured T cells was also 
examined under defined divalent cation conditions, which in- 
cluded the presence of both Ca  2+ and Mg  2+, Ca  2+ only, Mg  2+ 
only, and the absence of both divalent cations. These experi- 
ments were carried out in the presence of two control anti- 
CD1 la antibodies,  mAb 24,  which has  been  shown to be 
Mg  2+ dependent for binding to T cells, and mAb 38, which 
is independent of divalent cations for its binding specificity 
(Dransfield and Hogg, 1989). The two control antibodies ex- 
hibited their expected cation dependency in this experiment. 
The  results  depicted  in  Fig.  6  showed  clearly  that  mAb 
MEM-83 staining was indistinguishable from mAb 38, indi- 
cating that mAb MEM-83 was not dependent upon divalent 
cations for recognition of its epitope. 
MEM-8~ 
~2U.5.  . 
....  ....  .... 
Figure  5.  MEM-83  induces 
expression  of the  "activation 
reporter" 24 epitope on LFA- 
1. T cells were preincubated at 
37~  for 30 min in the pres- 
ence  of 2  ~g/ml  of purified 
mAbs  indicated,  or  50  nM 
PdBu,  in Hepes-buffered  me- 
dium containing 1 mM Mg  2+ 
and 1 mM EGTA. Cells were 
then washed and stained  with 
FITC-conjugated mAb 24 for 
immunocytometfic  detennina- 
tion of 24 epitope expression.  Nonreactive mAb 52U and PdBu 
were included as negative and positive  controls of 24 expression. 
Immunofluorescence histograms of a single experiment are shown, 
representative  of four similar experiments. 
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Figure 6. Expression of the MEM-83 epitope is not Ca  2+ or Mg  2+ 
dependent.  T cells were preincubated at 370C for 30 min in Hepes- 
buffered medium supplemented  with appropriate additions of I mM 
CaCI2,  MgCI2,  EDTA,  or  EGTA.  Divalent  cation-conditioned 
cells were subsequently  evaluated for immunofluorescence,  as de- 
scribed in the legend to Fig. 5, using primary mAbs MEM-83, 24, 
38, and 52U. Control mAbs 24 and 38 recognize epitopes that have 
been previously shown to be dependent and independent,  respec- 
tively,  of Ca  2+ and Mg  2+ cations (Dransfield  and Hogg,  1989). 
Results  of a  single  experiment are shown,  representative  of two 
similar  experiments. 
mAb MEM-83 Requires the Presence of  Mg  2+ to Exert 
Its ICAM-I Binding Effect 
The high affinity interaction between LFA-1  on T  cells and 
ICAM-1 has previously been shown to be regulated by the 
presence  of divalent  cations  in the  extracellular  medium, 
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T cells were labeled with 5tCr and conditioned in medium con- 
taining 1 mM CaCI2 or MgCI2/EGTA, as described in the legend 
to Fig. 6.  Cells were subsequently evaluated for their ability to 
bind ICAM-1Fc-coated 96-well plates at 37~  for 30 min, in the 
absence of stimuli or in the presence of 2 ~g/ml mAb MEM-83 or 
50 nM PdBu. Bars  represent the average + SD percentage ofT cells 
binding to ICAM-I (n = 4), relative to total counts obtained by de- 
tergent lysis. 
particularly Mg  2+ (Marlin and Springer, 1987; Dransfield et 
al.,  1992a). We therefore investigated whether mAb MEM- 
83 could induce T cells to bind ICAM-1  in the presence of 
either of these divalent cations. These experiments demon- 
strated clearly that, despite exhibiting no divalent cation de- 
pendency for recognition of its epitope, mAb MEM-83 did 
require the presence of Mg  2+ to induce binding to ICAM-1 
(Fig. 7), a requirement that it shares with other known stimu- 
lators of the LFA-1/ICAM-1 adhesion pathway,  such as PdBu 
(Martz et al.,  1980; Rothlein and Springer,  1986). 
mAb MEM-83 Maps to the I Domain 
To identify sequences within the extracellular domain of the 
LFA-1  ct  subunit that  might be involved in  regulating the 
avidity of ligand binding, we mapped the MEM-83 epitope 
using an in vitro-translated CDlla cDNA deletion series. 
The cDNA deletion series used in these mapping studies was 
designed to create a series of protein fragments containing 
successive  single-domain  deletions,  beginning  from  the 
NH2 terminus of the LFA-1 c~ chain (Fig. 8 a). Protein frag- 
ments  were  radiolabeled  with  [35S]methionine  during  in 
vitro translation,  immunoprecipitated with mAb MEM-83 
or an irrelevant anti-CD8 mAb 14, and immunoprecipitated 
proteins separated by SDS-PAGE. This mapping approach 
has been previously used to localize the epitopes of several 
functionally distinct anti-CDlla  mAbs  (Stanley,  P.,  J.  E. 
Harvey, P. A. Bates, R. I. Bennet, and N. Hogg, manuscript 
in preparation). The results depicted in the upper panel of 
the autoradiogram in Fig. 8 b demonstrated that mAb MEM- 
83 immunoprecipitated protein fragments containing the I 
domain,  but not fragments from which the I  domain was 
deleted.  Nonspecific binding with  mAb  14 was  minimal. 
Efficiency of translation and incorporation of radiolabel by 
each protein fragment was checked by analysis of the nonim- 
munoprecipitated fraction of the translation mixes and was 
shown to be comparable across the entire deletion series 
(Fig. 8 B, lower  panel). Although in vitro translation gener- 
ated some truncated protein fragments in addition to the full- 
length translation products, only full-length products (marked 
by an arrow) were immunoprecipitated by mAb MEM-83. 
To show that the I domain is both necessary and sufficient 
for recognition by mAb  MEM-83,  a  3' deletion fragment 
containing only domain II plus the I domain was constructed 
and also shown to be immunoprecipitated by mAb MEM-83 
(data not shown). The LFA-1 activation epitope recognized 
by mAb MEM-83 therefore mapped to the I domain. 
Discussion 
From a  panel of 21  CDlla  and  10 CD18  mAbs,  we have 
identified  a  unique  anti-CDlla  mAb,  MEM-83,  which 
directly induces LFA-1 binding to ICAM-1.  This ICAM-1 
binding could also be achieved by monovalent Fab fragments 
of mAb MEM-83 at concentrations equivalent to whole anti- 
body, was associated with appearance of the 24 "activation 
reporter"  epitope  on  LFA-1, and  could  be  inhibited  by 
anti-ICAM-1  and anti-LFA-1 blocking antibodies.  Similar 
observations have been made for the platelet integrin gpllb- 
IIIa, in which case the two mAbs P41 and Ab62 are able to 
induce binding to ligand fibrinogen and expression of an acti- 
vation epitope PAC-1 (Shattil et al.,  1985;  O'Toole et al., 
1990). 
In contrast to the results obtained using purified ICAM-1 
as a  screen for LFA-1/ICAM-l-dependent adhesion, it was 
notable  that  the  parallel  screen using  the  assay  of mAb- 
induced homotypic aggregation generated a large number of 
"false positive" activating mAbs. In this model, 11 of the 12 
anti-CD1 la mAbs that caused aggregation were not able to 
induce binding to immobilized ICAM-1.  In the case of one 
such false positive, mAb 38,  we were able to demonstrate 
that  homotypic  aggregation  was  caused  by  cross-linking 
events associated with bivalent antibody; inasmuch as homo- 
typic aggregation could not be achieved by monovalent Fab 
fragments of 38,  aggregation with whole antibody was not 
accompanied by expression of the "activation reporter" 24 
epitope and aggregation was  not inhibited by anti-ICAM-1 
blocking antibodies.  It remains theoretically possible that 
some of the false positive mAbs induced a conformation of 
LFA-1 which conferred binding exclusive to counter-recep- 
tors other than ICAM-1,  such as ICAM-2 and ICAM-3. This 
possibility remains to be tested with appropriate blocking 
antibodies. Alternatively, the conclusion that bivalent mAb 
38 mediates homotypic aggregation in a cross-linking-depen- 
dent manner is supported by the careful study of Cyster and 
Williams (1992), which showed an absolute requirement for 
mAb cross-linking in homotypic lymphocyte aggregation trig- 
gered by anti-CD43 mAbs. Moreover, several recent studies 
have invoked a role for unknown adhesion structures to ex- 
plain homotypic aggregation events triggered by bivalent anti- 
bodies without rigorously excluding the possibility that these 
events could be mediated by cross-linking epitopes on adja- 
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tope maps to the I domain of 
the LFA-1 ~ subunit.  (A) The 
cDNA deletion  series used in 
these  mapping  studies  con- 
sisted  of  five  NH2-terminal 
fragments  and  one  COOH- 
terminal fragment of  the LFA-1 
c~ subunit.  The NH2-terminal 
series (labeled N, II, "I" DOM, 
11I, and IV) was constructed 
to  contain  successive  single 
domain  deletions,  beginning 
from the NH2 terminus of the 
LFA-I c~ subunit and each frag- 
ment  terminating  in  domain 
VII. The COOH-terminal frag- 
ment  (C)  spanned  from the 
end of the repeating  domains 
to the transmembrane region. 
Numbers designate the nucleo- 
tide position of  the 5'and 3'ter- 
mini of  each cDNA construct. 
Domain boundaries were as- 
signed according to the desig- 
nations of  Larson et al. (1989). 
(B)  The  cDNAs depicted  in 
Fig.  8 A were used to create 
a corresponding series of pro- 
tein fragments by in vitro tran- 
scription and translation  in the 
presence  of [35S]methionine. 
Radiolabeled  protein  frag- 
ments  were  immunoprecipi- 
tated by mAb MEM-83 or ir- 
relevant  anti-CD8  mAb  14, 
harvested on protein A-Sepha- 
rose, washed, and analyzed on 
a 9 % SDS-PAGE gel run under 
reducing  conditions  (upper 
panel).  Efficiency  of transla- 
tion and incorporation of  radio- 
label  by  each  fragment  was 
checked by SDS-PAGE of the 
nonimmunoprecipitated  frac- 
tion  of each translation  mix 
(lower panel).  Protein  frag- 
ments corresponding to the ex- 
pected molecular size for a fi~- 
length translation  product are 
indicated by arrows. Autoradio- 
grams  from a  single  experi- 
ment are  shown,  representa- 
tive of  five similar experiments. 
cent cells.  This present study underlines the importance of 
using rigorously purified Fab fragments when using antibod- 
ies  to define novel  activation epitopes  on adhesion  mole- 
cules. 
Several previous studies have shown that homotypic aggre- 
gation triggered by phorbol esters  served as a  good model 
of LFA-1/ICAM-l-dependent adhesion and could be used to 
screen for anti-LFA-1 mAbs (Rothlein and Springer,  1986; 
Cobbold et al.,  1987; Schmidt,  1989). Our observations are 
not in conflict with these past reports, in that when we used 
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the aggregation screen correctly identified 18  anti-LFA-1 
(CDlla/CD18)  blocking  mAbs  (including  all  previously 
reported blocking mAbs) without any false positives (data 
not shown). These results suggest that the activation state of 
the cell may be a crucial factor in determining the aggrega- 
tion phenotype of the mAb and LFA-1/ICAM-I dependency 
of the adhesion process observed. The reason for such acti- 
vation dependence in homotypic adhesion processes is not 
yet understood but it can be speculated to be due to differ- 
ences in the distribution or clustering of adhesion receptors. 
Homotypic aggregation should therefore be used with cau- 
tion as a model for LFA-1/ICAM-l-dependent adhesion. 
A comparison of the activation epitopes recognized by the 
CDlla-specific mAbs MEM-83 and NKI-L16 (Keizer et al., 
1988; van Kooyk  et al., 1991) indicated that the two antibod- 
ies recognized functionally distinct epitopes. Whereas the 
NKI-L16 epitope has been reported to be present only at low 
levels on freshly isolated leukocytes, the MEM-83 epitope 
was constitutively expressed on fleshly isolated T cells and 
monocytes. In addition, expression of the MEM-83 epitope 
was  completely independent of the  divalent cations  Ca  2§ 
and Mg  2§  whereas the NKI-L16 epitope was Ca  2§ depen- 
dent for its recognition.  Furthermore, using an in vitro- 
translated CD1 la cDNA deletion series, we were able to map 
the activation epitope recognized by mAb MEM-83 to the 
I domain of the LFA-1 ot subunit. In contrast, evidence de- 
rived from tryptic cleavage studies suggested that the NKI- 
L16 epitope may be located close to the membrane (Keizer 
et al.,  1988). 
Localization of  the MEM-83 activation epitope to the I do- 
main of the LFA-1 tx subunit suggests for the first time that 
this domain may be involved in regulating the interconver- 
sion between the high- and low-avidity ligand-binding con- 
formations of LFA-1. Although models for integrin structure 
are still at a preliminary stage (Calvete et al., 1992),  it can 
be speculated that the I domain inserted between LFA-1 do- 
mains II and III might be in a position to influence the "avail- 
ability" of the divalent cation binding domains V-VII,  per- 
haps  by  inducing  an  allosteric  alteration  in  the  tertiary 
folding of LFA-1 and either revealing these domains or alter- 
ing their ability to bind divalent cation. 
A  further  speculation  would  be  that  binding  of mAb 
MEM-83 may achieve from the exterior of the cell a similar 
alteration in the tertiary structure of LFA-1 as the "inside- 
out" signal triggers from within the cell. Thus, binding of 
mAb MEM-83 may lead to exposure, via allosteric changes 
to the tertiary structure, of ligand contact points anywhere 
on the LFA-1 receptor including the I domain itself. Indeed 
the three mAbs which can cause LFA-1 activation-MEM- 
83, NKI-L16,  and KIM-127-all interact with separate epi- 
topes on the o~ and ~  subunits, suggesting that very wide- 
spread alterations in LFA-1 conformation occur upon activa- 
tion and that changes affecting ligand binding ability might 
take place at sites distant from the activation epitopes. 
In  summary,  we  have  identified an  anti-CDlla  mAb, 
MEM-83, which is capable of directly inducing the ICAM-1 
binding  conformation  of  LFA-1. The  activation  epitope 
defined by mAb MEM-83 was mapped to the I domain of  the 
LFA-1 ot subunit, suggesting for the first time that this do- 
main may play either a  regulatory or even a direct ligand 
binding role in the binding of ICAM-1 by LFA-1. Studies de- 
signed to more precisely delineate the involvement of the I 
domain during LFA-1 activation are currently in progress. 
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